X

Trial Profile

FOLFIRI + Erbitux versus alternating FOLFIRI + Erbitux/FOLFOX + Erbitux to patients with RAS wild type metastatic colorectalcancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Calcium carbonate; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms Nordic-8

Most Recent Events

29 Oct 2020 Status changed from active, no longer recruiting to completed.
05 Dec 2019 This trial is completed in Sweden (Global End Date: 1 Mar 2019), according to European Clinical Trials Database record.
21 Oct 2019 This trial has been completed in Denmark As per EudraCT Record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com